TIKOMED granted Orphan Medicinal Drug Designation for ILB [® ]for the treatment of amyotrophic lateral sclerosis by the European Commission
Viken – 28[th] August 2020 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced that the European Commission has granted Orphan Drug Designation to its lead drug candidate ILB® for the treatment of patients with amyotrophic lateral sclerosis (ALS) – a terminal, neurodegenerative disease where most patients die of respiratory muscle weakness in less than three to five years from symptom onset and for which there is yet no cure. Orphan Drug Designation (ODD) in the European Union (EU) is granted by the European Commission based on a positive opinion issued by the